Skip to content

Study · Not a test of the peptide alone · 2023

5 results

Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis.

Otin J, Tran NT, Benoit A, Buisson C, Taverna M

Electrophoresis27 Feb 2023Cited by 11 (Europe PMC)

PMID36787346 (opens in a new tab)DOI10.1002/elps.202200278 (opens in a new tab)PepBankPUB-36787346
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 01LabNot a test of Sermorelin aloneIn vitro (cell-free)Other

    In capillary electrophoresis, dimethyl-β-cyclodextrin as chiral selector separated GHRH analogs, including the enantiopeptides sermorelin and CJC-1293.

    In plain wordsIn lab tests, a chemical additive separated sermorelin from CJC-1293, a peptide that differs in the chirality of only one amino acid.

    Peptide
    Sermorelin
    Outcome
    Not applicableChiral separation of sermorelin and CJC-1293
    Study

    n: not reported in source

    capillary electrophoresis
    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    Dimethyl-β-cyclodextrin used as a chiral selector allowed, for the first time, the separation of those basic peptide analogs, including enantiopeptides (sermorelin and CJC-1293) that differ by the chirality of only one amino acid.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02LabNot a test of Sermorelin aloneIn vitro (cell-free)Other

    The optimized PS-LVSS preconcentration with chiral capillary zone electrophoresis separated the GHRH analogs with limits of detection of 75 to 200 ng/mL.

    In plain wordsIn lab tests, the method detected GHRH analog peptides, sermorelin among them, at 75 to 200 ng/mL.

    Peptide
    Sermorelin
    Outcome
    Not applicableLimit of detection of GHRH analogs
    Study

    n: not reported in source

    capillary electrophoresis
    Outcome group
    Analytical methods and detection · Pharmacology

    Measurements

    limit of detection
    75 to 200 ng/mL
    GHRH analogs, PS-LVSS with CZE

    Source sentences

    Summary
    Finally, using a combination of the optimized PS-LVSS preconcentration with the chiral capillary zone electrophoresis (CZE), the GHRH analogs were separated and limits of detection between 75 and 200 ng/mL were reached.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  3. 03LabNot a test of Sermorelin aloneIn vitro (cell-free)Other

    In desalted urine spiked with sermorelin, the signal enhancement factor was 640 compared with chiral CZE without preconcentration.

    In plain wordsIn lab tests, the method raised the sermorelin signal in urine 640-fold compared with the method without preconcentration.

    Peptide
    Sermorelin
    Outcome
    IncreaseSignal enhancement factor in desalted urine spiked with sermorelin
    Study

    n: not reported in source

    capillary electrophoresis
    Comparator
    CZE without preconcentration
    Outcome group
    Analytical methods and detection · Pharmacology

    Measurements

    signal enhancement factor
    640 fold
    desalted urine spiked with sermorelin

    Source sentences

    Summary
    SEF of 640 was obtained with desalted urine spiked with sermorelin by comparison to the CZE (without preconcentration) method.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  4. 04LabNot a test of Sermorelin aloneIn vitro (cell-free)Other

    Large volume sample stacking with polarity switching gave a better signal enhancement factor than sweeping for the GHRH analogs.

    In plain wordsIn lab tests, one concentration method gave a stronger signal than another for GHRH analog peptides.

    Peptide
    Sermorelin
    Outcome
    Not applicableLarge volume sample stacking versus sweeping
    Study

    n: not reported in source

    capillary electrophoresis
    Comparator
    Sweeping
    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    The large volume sample stacking with polarity switching (PS-LVSS) method with an injected sample volume corresponding to 80% of the capillary one was found superior to the sweeping in terms of signal enhancement factor (SEF).

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  5. 05LabNot a test of Sermorelin aloneIn vitro (cell-free)Other

    Adding acid and organic solvent to the sample led to a twofold signal improvement compared with water as matrix.

    In plain wordsIn lab tests, an acid and methanol sample matrix doubled the signal compared with water.

    Peptide
    Sermorelin
    Outcome
    IncreaseEffect of sample matrix on signal
    Study

    n: not reported in source

    capillary electrophoresis
    Comparator
    Water
    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    Acid and organic solvent addition to the sample (0.1 mM phosphoric acid with 30% methanol) led to a twofold signal improvement, when compared to water as a matrix.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.